The financials
NeoGenomics, Inc. by the numbers
NeoGenomics, Inc. (NEO) reported revenue of $202M in Q2 2026 (quarter ended Jun 30, 2026), up 11% from the same quarter a year earlier. That came with a gross margin of 46% and net income of $2.2M (1.1% of revenue). For the full year FY2025, revenue was $727M (+10% year on year) and net income −$108M. Its largest product in Q2 2026 was Client Direct Billing at $138M, 68% of the disclosed total, well ahead of Commercial Insurance at 18%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $202M | $181M | +11% |
| Gross profit | $92M | $77M | +19% |
| Operating income | −$9.8M | −$48M | n/a |
| Net income | $2.2M | −$45M | to a profit |
| Diluted EPS | $0.02 | −$0.35 | to a profit |
| Product | Revenue | Share |
|---|---|---|
| Client Direct Billing | $138M | 68% |
| Commercial Insurance | $36M | 18% |
| Medicare And Other Governmental | $27M | 14% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $201.7M (+8.0%)
Medicare And Other Governmental grew +28% year on yearSelf Pay Services -100% year on year
Segment Latestquarter on quarteryear on year
- Client Direct Billing$138.0M$138.0MQoQ +4.8%year on year +5.2%+4.8%+5.2%
- Commercial Insurance$36.3M$36.3MQoQ +17%year on year +26%+17%+26%
- Medicare And Other Governmental$27.4M$27.4MQoQ +14%year on year +28%+14%+28%
- Self Pay Services$0.00$0.00QoQ -year on year -100%--100%
Diagnostics & Research
Ranks #12 of 17 by Smart Score